StockData
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc. (TARS) company profile

TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/304% above fair value
$78.20−0.48 (-0.61%)

Close on Nov 17, 2026Market cap $3.43BP/E –Yield 0.00%

About Tarsus Pharmaceuticals

Biological Products, (No Diagnostic Substances), SIC 2836

The company is a commercial-stage biopharmaceutical business focused on developing and commercializing therapeutics, primarily targeting eye care and infectious disease prevention. Its primary commercial product is XDEMVY, an FDA-approved prescription ophthalmic solution that treats Demodex blepharitis by eradicating Demodex mites through GABA-Cl channel inhibition. Additionally, the business develops investigational formulations using the lotilaner active pharmaceutical ingredient, including a topical gel candidate for ocular rosacea and an oral tablet candidate designed for Lyme disease prophylaxis. Its commercialized offerings serve patients presenting with mite infestations and ocular conditions, prescribed directly by eye care professionals such as ophthalmologists and optometrists.

Commercial operations are primarily focused in the United States, where XDEMVY is actively marketed and sold via a dedicated specialty sales force. Beyond its core domestic presence, international expansion efforts include licensing partnerships in Greater China, alongside development and regulatory pursuits targeting approval in Europe and Japan. The provided text does not disclose the location of the company's headquarters or its founding year.

Summary of the business section of Tarsus Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Tarsus Pharmaceuticals, Inc.
Headquarters
Irvine, CA
Address
15440 Laguna Canyon Road 92618
Phone
(949) 409-9820
Employees
370, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst& Young LLP, Irvine, California

Stock & identifiers

Ticker
TARS
Exchange
Nasdaq
IPO date
Oct 16, 2020
Shares outstanding
44M, Jul 30, 2026
Public float
$1.70B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1819790
CUSIP
87650L103
ISIN
US87650L1035
FIGI
BBG00RB9BNQ7
Share class FIGI
BBG00RB9BNR6
EIN
81-4717861

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Bobak R. AzamianPresident/CEO and Board Chair, Director851,412
Neera ClaseChief Commercial Officer14,800
Seshadri NeervannanChief Operating Officer79,007
Elizabeth Yeu LinChief Medical Officer16,177
Jeffrey S. FarrowSee Remarks56,801
Dianne C. WhitfieldChief Human Resources Officer35,028
Bryan WahlGeneral Counsel63,959
Aziz MottiwalaChief Commercial Officer61,480
David E. I. PyottDirector10,958
William J. Link PhdDirector106,987
Wendy L. YarnoDirector16,956
Bhaskar ChaudhuriDirector11,654
Scott W. MorrisonDirector13,654
Katherine GoodrichDirector2,233
Andrew D. GoldbergDirector19,654

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$6.62M$31.09M$2.66M$364$125
FY2024$7.90M$19.75M$3.17M$246$93
FY2023$3.13M$4.50M$2.57M$90$94

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Bobak Azamian
President, Chief Executive Officer and Board Chairman
$726.33K$2.65M$2.65M$555.70K$36.18K$6.62M-16%
Jeffrey Farrow
Chief Financial Officer and Chief Strategy Officer
$541.67K$893.96K$895.01K$264.90K$82.08K$2.68M-17%
Seshadri Neervannan
Chief Operating Officer
$547.00K$893.96K$895.01K$267.30K$24.90K$2.63M-18%
Aziz Mottiwala
Chief Commercial Officer
$529.25K$983.36K$984.52K$260.10K$32.30K$2.79M-11%
Bryan Wahl
General Counsel
$500.83K$893.96K$895.01K$245.50K$24.90K$2.56M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 16, 2020
Offer price
$16.00
Securities offered
5,500,000
Gross proceeds
$88.00M
Exchange
Nasdaq
First trading day
Oct 16, 2020
First-day close
$20.58+28.6%
Lock-up ends (est.)
Apr 14, 2021

“The initial public offering price is $16.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 370 full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?